Today is 2023-03-24

Study on Bowel preparation quality and adenoma detection rate of Prepopik in patients with constipation
download

注册号:

Registration number:

ChiCTR2300068005 

最近更新日期:

Date of Last Refreshed on:

2023-02-02 

注册时间:

Date of Registration:

2023-02-02 

注册号状态:

预注册  

Registration Status:

Prospective registration  

注册题目:

复方匹可硫酸钠对便秘患者肠道准备质量及腺瘤检出率的研究 

Public title:

Study on Bowel preparation quality and adenoma detection rate of Prepopik in patients with constipation 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

复方匹可硫酸钠对便秘患者肠道准备质量及腺瘤检出率的研究:一项随机对照试验 

Scientific title:

Study on Bowel preparation quality and adenoma detection rate of Prepopik in patients with constipation:A randomized controlled trial 

研究课题代号(代码):

Study subject ID:

 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

甘日云 

研究负责人:

姚君 

Applicant:

Gan Riyun 

Study leader:

Yao Jun 

申请注册联系人电话:

Applicant telephone:

13723584507 

研究负责人电话:

Study leader's telephone:

15914095696 

申请注册联系人传真 :

Applicant Fax:

 

研究负责人传真:

Study leader's fax:

 

申请注册联系人电子邮件:

Applicant E-mail:

2394438179@qq.com 

研究负责人电子邮件:

Study leader's E-mail:

yao.jun@szhospital.com 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

广东省深圳市罗湖区深圳市人民医院东门北路1017号  

研究负责人通讯地址:

广东省深圳市罗湖区深圳市人民医院东门北路1017号  

Applicant address:

1017 Dongmen Road, Luohu District, Shenzhen, Guangdong, China 

Study leader's address:

1017 Dongmen Road, Luohu District, Shenzhen, Guangdong, China 

申请注册联系人邮政编码:

Applicant postcode:

 

研究负责人邮政编码:

Study leader's postcode:

 

申请人所在单位:

暨南大学第二临床医学院(深圳市人民医院) 

Applicant's institution:

The Second Clinical Medicine College (Shenzhen People's Hospital) of Jinan University  

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

LL-KY-2021891-01号 

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市人民医院科研伦理委员会 

Name of the ethic committee:

Scientific Research Ethics Committee of Shenzhen People's Hospital 

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-14 

伦理委员会联系人:

珞瑜 

Contact Name of the ethic committee:

Luo Yu 

伦理委员会联系地址:

深圳市东门北路1017号9栋3楼伦理办公室315 

Contact Address of the ethic committee:

315, Ethics Office, 3rd Floor, Building 9, No. 1017, North Dongmen Road, Shenzhen 

伦理委员会联系人电话:

Contact phone of the ethic committee:

0755-22943881 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

195323995@qq.com 

研究实施负责(组长)单位:

暨南大学第二临床医学院(深圳市人民医院) 

Primary sponsor:

The Second Clinical Medicine College (Shenzhen People's Hospital) of Jinan University  

研究实施负责(组长)单位地址:

广东省深圳市罗湖区深圳市人民医院东门北路1017号  

Primary sponsor's address:

1017 Dongmen Road, Luohu District, Shenzhen, Guangdong, China 

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市人民医院

具体地址:

广东省深圳市罗湖区深圳市人民医院东门北路1017号

Institution
hospital:

Shenzhen People's Hospital

Address:

The Second Clinical Medicine College (Shenzhen People's Hospital) of Jinan University

经费或物资来源:

深圳市科技创新基金(JCYJ20210324113215040) 

Source(s) of funding:

Shenzhen Science and Technology Innovation Fund (JCYJ20210324113215040) 

研究疾病:

便秘 

Target disease:

constipation 

研究疾病代码:

 

Target disease code:

 

研究类型:

干预性研究 

Study type:

Interventional study 

研究所处阶段:

其它 

Study phase:

N/A 

研究目的:

本研究通过比较复方匹可硫酸钠与复方聚乙二醇电解质散在便秘患者中的肠道准备质量、腺瘤检出率、患者耐受性的差异等指标,为便秘患者的肠道准备提供方向。 

Objectives of Study:

In this study, the difference of intestinal preparation quality, adenoma detection rate, tolerance and other indicators between Prepopik and compound polyethylene glycol electrolyte powder in patients with constipation were compared to provide directions for intestinal preparation in patients with constipation. 

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

研究设计:

随机平行对照 

Study design:

Parallel 

纳入标准:

①满18周岁以上(含18岁),男女不限;②诊断为便秘者;③愿意接受结肠镜检测;④签署知情同意书。 

Inclusion criteria

①Over 18 years old (including 18 years old), both male and female; ② Patients diagnosed with constipation; ③ Willing to undergo colonoscopy; ④ Sign the informed consent form. 

排除标准:

①完全性肠梗阻;②严重活动性出血性结肠病变患者;③肠穿孔;④腹膜炎;⑤腹腔动脉瘤;⑥妊娠期妇女;⑦拒绝做结肠镜或不能配合做结肠镜者 

Exclusion criteria:

①Complete intestinal obstruction; ② Patients with severe active hemorrhagic colopathy; ③ Intestinal perforation; ④ peritonitis; (5) Abdominal aneurysm; ⑥ Pregnant women; ⑦ Refuse to do colonoscopy or can not cooperate to do colonoscopy 

研究实施时间:

Study execute time:

From2023-02-05To 2024-02-05 

征募观察对象时间:

Recruiting time:

From2023-02-05To 2024-02-05 

干预措施:

Interventions:

组别:

复方匹可硫酸钠组

样本量:

110

Group:

Prepopik Group

Sample size:

干预措施:

肠镜检查前予复方匹可硫酸钠行肠道准备

干预措施代码:

Intervention:

The intestine was prepared by Prepopik before colonoscopy

Intervention code:

组别:

复方聚乙二醇电解质散组

样本量:

110

Group:

Compound polyethylene glycol electrolyte powder group

Sample size:

干预措施:

肠镜检查前予复方聚乙二醇电解质散行肠道准备

干预措施代码:

Intervention:

The bowel was prepared with compound polyethylene glycol electrolyte powder before colonoscopy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国 

省(直辖市):

广东 

市(区县):

深圳 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen People's Hospital  

Level of the institution:

Third-class Hospital 

测量指标:

Outcomes:

指标中文名:

肠道准备质量

指标类型:

主要指标 

Outcome:

bowel preparation quality

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腺瘤检出率

指标类型:

次要指标 

Outcome:

Detection rate of adenoma

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者耐受性

指标类型:

次要指标 

Outcome:

Patient tolerance

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

结直肠息肉

组织:

结直肠

Sample Name:

Colorectal polyp

Tissue:

colorectum

人体标本去向

其它 

说明

切除送检

Fate of sample:

Others 

Note:

Excision and examination

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用SPSS函数组随机数功能生成随机数,再利用spss将进行分割,最终分为2组

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS function group was used to generate random numbers, which were then used to segment the data and finally divided into two group

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results ater
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台 (http://www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan research manager (http://www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用CRF表收集数据,由3名研究者(甘日云、熊锋、师瑞月)完成,并由1名研究者(王立生)进行核查。最终数据由2名研究者(姚君、李德锋)将上述数据库录入并提交至ResMan临床试验公共管理平台(预计时间为2023年12月31日前)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection will be finished by Riyun Gan,Feng Xiong, Ruiyue Shi, and CRF will be used. Then, the data will be verified by Lisheng Wang. Last, the data will be submitted to ResMan by Jun Yao and Defeng Li after the completion of the trail (expected deadline is December 31, 2023).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-02-02
return list